Loading...
ACS Chemical Neuroscience Molecule Spotlight on Valdoxen
[Image: see text] A new and novel non-SSRI potential treatment option for major depressive disorders is Valdoxen (agomelatine) which is currently in phase III clinical studies. Valdoxen is a norepinephrine disinhibitor (NNDI) and is also an antagonist of the 5-HT(2C) receptor.
Na minha lista:
| Hovedforfatter: | |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Chemical Society
2010
|
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3368641/ https://ncbi.nlm.nih.gov/pubmed/22778814 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/cn100062j |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|